Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner

Nanomedicine and Nanoscale Delivery (Focus Group – NND)

Microfluidic Production of PLGA@Lipid Hybrid Nanoparticles for Co-Delivery of Two Anticancer Agents

Simona Barone – PhD student, Department of Pharmacy, University of Naples Federico II; Margherita Brindisi – Associate Professor, Department of Pharmacy, University of Naples Federico II; Thomas Moore – Assistant Professor, Department of Pharmacy, University of Naples Federico II

    Poster Presenter(s)

  • Simone Misto, n/a

    PhD student
    University of Naples Federico II, United States

Introduction:

Polylactide-co-glycolide (PLGA) nanoparticles (NP) are widely used in nanomedicine for controlled release of an active pharmaceutical ingredient (API), improve API pharmacokinetics, and increase maximum tolerated dose.1 A major utility of PLGA NP is their capacity to load and control the release of hydrophobic small molecules, e.g. for the delivery of chemotherapeutics. Here, we set out to develop a hybrid lipid-coated PLGA NP (PLGA@Lipid) platform via microfluidics to co-deliver docetaxel (DTX) with a novel epigenetic modulator F2F-2292-4 in optimized therapeutic combinations for treatment against of MDA-MB-231 triple-negative breast cancer cells.

Learning Objectives:

  • Evaluate the structure-function relationship between nanoparticle production and co-loading of small molecules
  • Identify synergystic combinations of DTX with a novel anticancer agent against triple-negative breast cancer
  • Examine the capacity of the nanocarrier co-load therapeutics and control their release